Nurix prices 24.5M shares at $10.21 in underwritten registered offering

Nurix Therapeutics (NRIX) announced the pricing of its underwritten registered offering of 24,485,799 shares of its common stock at a price of $10.21 per share. The gross proceeds to Nurix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix, are expected to be $250M. The offering is expected to close on or about October 23, subject to the satisfaction of customary closing conditions. All of the securities are being offered by Nurix. The offering includes participation from both new and existing investors including General Atlantic, Redmile Group, Braidwell, Deep Track Capital, Perceptive Advisors, Trails Edge Capital Partners and Vestal Point Capital, as well as other healthcare-dedicated funds. J.P. Morgan Securities, Jefferies and Stifel, Nicolaus & Company are acting as joint book-running managers for the offering. Oppenheimer & Co. and Robert W. Baird & Co. are acting as lead managers for the offering.